Orthopediatrics Corp (KIDS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $844.67M
Last updated: Nov 17, 2026 at 11:05 AM ET
Orthopediatrics Corp (KIDS) Earnings: Report Dates and Results
Orthopediatrics (KIDS) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Orthopediatrics reported EPS of -$0.23, above the -$0.25 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
KIDS has an expected report date of Feb 24, 2027.
KIDS Earnings Call
The latest KIDS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 36 quarters below that had an estimate, KIDS beat 21, missed 13 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $72.66M, up 18.6% from $61.25M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.23 | -$0.25 | -$0.25 - -$0.16 | +8.00% | Beat | N/A | 6 | 0 up, 3 down | Oct 27, 2026 | $72.66M |
| Jun 30, 2026 | -$0.26 | -$0.31 | -$0.38 - -$0.17 | +16.13% | Beat | N/A | 6 | 1 up, 2 down | Aug 4, 2026 | $70.51M |
| Mar 31, 2026 | -$0.42 | -$0.44 | -$0.55 - -$0.31 | +4.55% | Beat | N/A | 6 | 1 up, 2 down | Apr 30, 2026 | $59.36M |
| Dec 31, 2025 | -$0.26 | -$0.37 | -$0.40 - -$0.16 | +29.73% | Beat | N/A | 6 | 1 up, 1 down | Feb 26, 2026 | $61.60M |
| Sep 30, 2025 | -$0.24 | -$0.26 | -$0.27 - -$0.24 | +7.69% | Beat | N/A | 4 | 1 up, 2 down | Oct 28, 2025 | $61.25M |
| Jun 30, 2025 | -$0.11 | -$0.28 | -$0.38 - -$0.17 | +60.71% | Beat | N/A | 4 | 0 up, 2 down | Aug 5, 2025 | $61.08M |
| Mar 31, 2025 | -$0.39 | -$0.43 | -$0.50 - -$0.26 | +9.30% | Beat | N/A | 4 | 0 up, 1 down | May 7, 2025 | $52.41M |
| Dec 31, 2024 | -$0.29 | -$0.26 | -$0.34 - -$0.20 | -12.97% | Miss | N/A | 3 | 2 up, 0 down | Mar 4, 2025 | $52.67M |
| Sep 30, 2024 | -$0.18 | -$0.19 | -$0.30 - -$0.13 | +5.26% | Beat | N/A | 6 | 0 up, 0 down | Nov 6, 2024 | $54.57M |
| Jun 30, 2024 | -$0.23 | -$0.26 | -$0.38 - -$0.17 | +11.54% | Beat | N/A | 7 | 0 up, 0 down | Aug 5, 2024 | $52.80M |
| Mar 31, 2024 | -$0.34 | -$0.40 | -$0.53 - -$0.27 | +15.00% | Beat | N/A | 7 | 0 up, 1 down | May 6, 2024 | $44.69M |
| Dec 31, 2023 | -$0.23 | -$0.28 | -$0.36 - -$0.24 | +17.86% | Beat | N/A | 7 | 0 up, 0 down | Mar 6, 2024 | $37.61M |
| Sep 30, 2023 | -$0.13 | -$0.20 | -$0.26 - -$0.17 | +35.00% | Beat | N/A | 7 | 0 up, 0 down | Nov 6, 2023 | $39.97M |
| Jun 30, 2023 | -$0.19 | -$0.20 | -$0.31 - -$0.16 | +5.00% | Beat | N/A | 7 | 1 up, 0 down | Jul 31, 2023 | $39.56M |
| Mar 31, 2023 | -$0.29 | -$0.34 | -$0.44 - -$0.31 | +14.71% | Beat | N/A | 7 | 1 up, 0 down | May 1, 2023 | $31.59M |
| Dec 31, 2022 | -$0.35 | -$0.25 | -$0.34 - -$0.19 | -40.00% | Miss | N/A | 7 | 0 up, 0 down | Feb 28, 2023 | $30.99M |
| Sep 30, 2022 | -$0.05 | -$0.21 | -$0.27 - -$0.15 | +76.19% | Beat | N/A | 7 | 1 up, 0 down | Oct 31, 2022 | $34.95M |
| Jun 30, 2022 | -$0.17 | -$0.18 | -$0.26 - -$0.18 | +5.56% | Beat | N/A | 7 | 0 up, 0 down | Aug 3, 2022 | $32.93M |
| Mar 31, 2022 | -$0.30 | -$0.37 | -$0.44 - -$0.28 | +18.92% | Beat | N/A | 7 | 0 up, 0 down | May 4, 2022 | $23.42M |
| Dec 31, 2021 | -$0.24 | -$0.30 | -$0.39 - -$0.17 | +20.00% | Beat | N/A | 7 | N/A | Mar 2, 2022 | $24.81M |
| Sep 30, 2021 | -$0.15 | -$0.23 | -$0.45 - -$0.18 | +34.78% | Beat | N/A | 7 | 3 up, 0 down | Nov 3, 2021 | $25.08M |
| Jun 30, 2021 | -$0.11 | -$0.33 | -$0.47 - -$0.19 | +66.67% | Beat | N/A | 7 | N/A | Aug 4, 2021 | $26.70M |
| Mar 31, 2021 | -$0.25 | -$0.25 | -$0.35 - -$0.12 | 0.00% | In line | N/A | 7 | N/A | May 5, 2021 | $21.46M |
| Dec 31, 2020 | -$0.73 | -$0.27 | -$0.36 - -$0.19 | -170.37% | Miss | N/A | 7 | N/A | Mar 10, 2021 | $18.92M |
| Sep 30, 2020 | -$0.19 | -$0.31 | -$0.38 - -$0.24 | +38.71% | Beat | N/A | 7 | N/A | Nov 4, 2020 | $22.20M |
| Jun 30, 2020 | -$0.49 | -$0.38 | -$0.51 - -$0.25 | -28.95% | Miss | N/A | 7 | N/A | Aug 5, 2020 | $13.59M |
| Mar 31, 2020 | -$0.30 | -$0.22 | -$0.40 - -$0.18 | -36.36% | Miss | N/A | 6 | N/A | May 5, 2020 | $16.36M |
| Dec 31, 2019 | -$0.29 | -$0.22 | -$0.35 - -$0.20 | -31.82% | Miss | N/A | 8 | N/A | Mar 4, 2020 | $18.95M |
| Sep 30, 2019 | -$0.20 | -$0.16 | -$0.21 - -$0.13 | -25.00% | Miss | N/A | 6 | N/A | Nov 7, 2019 | $20.74M |
| Jun 30, 2019 | -$0.17 | -$0.08 | -$0.13 - -$0.05 | -112.50% | Miss | N/A | 7 | N/A | Aug 7, 2019 | $18.20M |
| Mar 31, 2019 | -$0.21 | -$0.17 | -$0.21 - -$0.13 | -23.53% | Miss | N/A | 6 | N/A | May 8, 2019 | $14.66M |
| Dec 31, 2018 | -$0.19 | -$0.19 | -$0.24 - -$0.12 | 0.00% | In line | N/A | 6 | N/A | Mar 6, 2019 | $14.57M |
| Sep 30, 2018 | -$0.15 | -$0.12 | -$0.16 - -$0.06 | -25.00% | Miss | N/A | 5 | N/A | Oct 31, 2018 | $15.82M |
| Jun 30, 2018 | -$0.21 | -$0.15 | -$0.17 - -$0.06 | -40.00% | Miss | N/A | 5 | N/A | Aug 8, 2018 | $15.08M |
| Mar 31, 2018 | -$0.41 | -$0.30 | -$0.37 - -$0.12 | -36.67% | Miss | N/A | 4 | N/A | May 14, 2018 | $12.09M |
| Dec 31, 2017 | -$3.82 | -$0.17 | -$0.24 - -$0.13 | N/A | N/A | N/A | 4 | N/A | Mar 7, 2018 | $11.68M |
| Sep 30, 2017 | -$0.13 | -$0.12 | N/A | -8.33% | Miss | N/A | N/A | N/A | Oct 16, 2017 | $12.38M |
| Jun 30, 2017 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 10, 2017 | $11.80M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.00, after -$1.04 the year before. It was -$4.18 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.00 | N/A |
| Dec 31, 2024 | -$1.04 | N/A |
| Dec 31, 2023 | -$0.84 | N/A |
| Dec 31, 2022 | -$0.87 | N/A |
| Dec 31, 2021 | -$0.75 | N/A |
| Dec 31, 2020 | -$1.71 | N/A |
| Dec 31, 2019 | -$0.87 | N/A |
| Dec 31, 2018 | -$0.96 | N/A |
| Dec 31, 2017 | -$4.18 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 10,000 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 10,002 | 12 | |
| 2026Q2 | Jun 30, 2026 | 8,659 | 13 | |
| 2026Q1 | Mar 31, 2026 | 7,782 | 12 | |
| 2025Q4 | Dec 31, 2025 | 5,518 | 10 | |
| 2025Q3 | Sep 30, 2025 | 6,337 | 8 | |
| 2025Q2 | Jun 30, 2025 | 5,280 | 6 | |
| 2025Q1 | Mar 31, 2025 | 8,030 | 9 | |
| 2024Q4 | Dec 31, 2024 | 6,348 | 8 |
2026Q3 Earnings Call
Opening remarks
Trip Taylor Company Representative Thank you for joining today's call. With me from the company are David R. Bailey, president and chief executive officer, and Fred L. Hite, chief operating and financial officer. Before we begin today, let me remind you that the company's remarks include forward-looking statements within the meaning of federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 2000. These forward-looking statements are subject to numerous risks and uncertainties, and the company's actual results may differ materially. For a discussion of those risk factors, I encourage you to review the company's most recent annual report on Form 10-K, which was filed with the SEC on March 4, 2026, and its subsequent quarterly reports on Form 10-Q. During the call today, management will also discuss certain non-GAAP financial measures, which are supplemental measures of performance. The company believes these measures provide useful information for investors in evaluating its operations period over period. For each non-GAAP financial measure referenced on this call, the company has included a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures in its third-quarter earnings release. Please note that the non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for OrthoPediatrics' financial results prepared in accordance with GAAP. In addition, the content on this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, today, October 27, 2026. Except as required by law, the company undertakes no obligation to revise or update any statements to reflect events or circumstances taking place after the date of this call. With that, I would like to turn the call over to David R. Bailey, president and chief executive officer.
David R. Bailey President and CEO Thanks, Trip. Good afternoon, everyone, and thank you for joining us today. This was an outstanding quarter for OrthoPediatrics. I want to begin with the metric that matters most to us. During the quarter, we helped nearly 42,000 children, bringing our total impact to over 1.4 million kids helped. I am proud of what our team and our clinical partners continue to accomplish. We are reaching more patients each day with our pediatric-focused products, increasing the quality of care, and improving outcomes for kids around the world. For the third quarter, we delivered record revenue of $72.7 million, up 19% over the prior year, with substantial growth across all of our businesses. Ongoing share gains across our legacy product portfolio served as a key driver alongside robust implant demand, a rapidly growing OPSB franchise, and strong overall international results.
Frequently Asked Questions About KIDS
When is Orthopediatrics's next earnings date?
Orthopediatrics's next earnings report is expected for Feb 24, 2027.
Did KIDS beat earnings estimates last quarter?
Yes. Orthopediatrics reported EPS of -$0.23 for the quarter ended Sep 30, 2026, above the -$0.25 estimate, a 8.00% surprise.
What EPS do analysts expect from KIDS next quarter?
The consensus EPS estimate for Orthopediatrics for the quarter ending Dec 31, 2026 is -$0.22 from 10 analysts, with estimates from -$0.25 to -$0.18.
How often does KIDS beat earnings estimates?
Orthopediatrics beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +15.39%.
KIDS pages: Overview, Earnings, Forecast, Financials, Valuation